APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drug Based on Gene Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drug Based on Gene Therapy Market Outlook and Growth Opportunities 2026

2 January 2026195 pages

Choose your research edition.

Industry ResearchDrug Based on Gene Therapy Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Based on Gene Therapy Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Drug Based on Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Based on Gene Therapy Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Drug Based on Gene Therapy Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Drug Based on Gene Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drug Based on Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drug Based on Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drug Based on Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drug Based on Gene Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drug Based on Gene Therapy market include Novartis, Biogen, Amgen, Sunway Biotech, Spark Therapeutics, SIBIONO, Sarepta Therapeutics, Orchard Therapeutics and Human Stem Cells Institute, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drug Based on Gene Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drug Based on Gene Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drug Based on Gene Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drug Based on Gene Therapy market.

Drug Based on Gene Therapy Segment by Company

Novartis

Biogen

Amgen

Sunway Biotech

Spark Therapeutics

SIBIONO

Sarepta Therapeutics

Orchard Therapeutics

Human Stem Cells Institute

Gilead Sciences

bluebird bio

AnGes

Alnylam Pharmaceuticals

Akcea Therapeutics

Drug Based on Gene Therapy Segment by Type

Viral Gene Therapy

Non-viral Gene Therapy

Drug Based on Gene Therapy Segment by Application

Neurological Diseases

Cancer

Other

Drug Based on Gene Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Drug Based on Gene Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drug Based on Gene Therapy key companies, revenue, market share, and recent developments.

3. To split the Drug Based on Gene Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drug Based on Gene Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drug Based on Gene Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Drug Based on Gene Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Based on Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Based on Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Based on Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drug Based on Gene Therapy industry.

Chapter 3: Detailed analysis of Drug Based on Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drug Based on Gene Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drug Based on Gene Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drug Based on Gene Therapy Industry Trends Table 2. Drug Based on Gene Therapy Industry Drivers Table 3. Drug Based on Gene Therapy Industry Opportunities and Challenges Table 4. Drug Based on Gene Therapy Industry Restraints Table 5. Global Drug Based on Gene Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drug Based on Gene Therapy Revenue Share by Company (2021-2026) Table 7. Global Drug Based on Gene Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drug Based on Gene Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Drug Based on Gene Therapy Company, Product Type & Application Table 10. Global Drug Based on Gene Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drug Based on Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Viral Gene Therapy Table 15. Significant Companies of Non-viral Gene Therapy Table 16. Global Drug Based on Gene Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Drug Based on Gene Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Drug Based on Gene Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Drug Based on Gene Therapy Sales Value Share by Type (2021-2026) Table 20. Global Drug Based on Gene Therapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Neurological Diseases Table 22. Significant Companies of Cancer Table 23. Significant Companies of Other Table 24. Global Drug Based on Gene Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Drug Based on Gene Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Drug Based on Gene Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Drug Based on Gene Therapy Sales Value Share by Application (2021-2026) Table 28. Global Drug Based on Gene Therapy Sales Value Share by Application (2027-2032) Table 29. Global Drug Based on Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Drug Based on Gene Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Drug Based on Gene Therapy Sales Value Share by Region (2021-2026) Table 32. Global Drug Based on Gene Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Drug Based on Gene Therapy Sales Value Share by Region (2027-2032) Table 34. Global Drug Based on Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Drug Based on Gene Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Drug Based on Gene Therapy Sales Value Market Share by Country (2021-2026) Table 37. Global Drug Based on Gene Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Drug Based on Gene Therapy Sales Value Market Share by Country (2027-2032) Table 39. Novartis Company Information Table 40. Novartis Business Overview Table 41. Novartis Drug Based on Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Novartis Drug Based on Gene Therapy Product Portfolio Table 43. Novartis Recent Development Table 44. Biogen Company Information Table 45. Biogen Business Overview Table 46. Biogen Drug Based on Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Biogen Drug Based on Gene Therapy Product Portfolio Table 48. Biogen Recent Development Table 49. Amgen Company Information Table 50. Amgen Business Overview Table 51. Amgen Drug Based on Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Amgen Drug Based on Gene Therapy Product Portfolio Table 53. Amgen Recent Development Table 54. Sunway Biotech Company Information Table 55. Sunway Biotech Business Overview Table 56. Sunway Biotech Drug Based on Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Sunway Biotech Drug Based on Gene Therapy Product Portfolio Table 58. Sunway Biotech Recent Development Table 59. Spark Therapeutics Company Information Table 60. Spark Therapeutics Business Overview Table 61. Spark Therapeutics Drug Based on Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Spark Therapeutics Drug Based on Gene Therapy Product Portfolio Table 63. Spark Therapeutics Recent Development Table 64. SIBIONO Company Information Table 65. SIBIONO Business Overview Table 66. SIBIONO Drug Based on Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. SIBIONO Drug Based on Gene Therapy Product Portfolio Table 68. SIBIONO Recent Development Table 69. Sarepta Therapeutics Company Information Table 70. Sarepta Therapeutics Business Overview Table 71. Sarepta Therapeutics Drug Based on Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sarepta Therapeutics Drug Based on Gene Therapy Product Portfolio Table 73. Sarepta Therapeutics Recent Development Table 74. Orchard Therapeutics Company Information Table 75. Orchard Therapeutics Business Overview Table 76. Orchard Therapeutics Drug Based on Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Orchard Therapeutics Drug Based on Gene Therapy Product Portfolio Table 78. Orchard Therapeutics Recent Development Table 79. Human Stem Cells Institute Company Information Table 80. Human Stem Cells Institute Business Overview Table 81. Human Stem Cells Institute Drug Based on Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Human Stem Cells Institute Drug Based on Gene Therapy Product Portfolio Table 83. Human Stem Cells Institute Recent Development Table 84. Gilead Sciences Company Information Table 85. Gilead Sciences Business Overview Table 86. Gilead Sciences Drug Based on Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Gilead Sciences Drug Based on Gene Therapy Product Portfolio Table 88. Gilead Sciences Recent Development Table 89. bluebird bio Company Information Table 90. bluebird bio Business Overview Table 91. bluebird bio Drug Based on Gene Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. bluebird bio Drug Based on Gene Therapy Product Portfolio Table 93. bluebird bio Recent Development Table 94. AnGes Company Information Table 95. AnGes Business Overview Table 96. AnGes Drug Based on Gene Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. AnGes Drug Based on Gene Therapy Product Portfolio Table 98. AnGes Recent Development Table 99. Alnylam Pharmaceuticals Company Information Table 100. Alnylam Pharmaceuticals Business Overview Table 101. Alnylam Pharmaceuticals Drug Based on Gene Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Alnylam Pharmaceuticals Drug Based on Gene Therapy Product Portfolio Table 103. Alnylam Pharmaceuticals Recent Development Table 104. Akcea Therapeutics Company Information Table 105. Akcea Therapeutics Business Overview Table 106. Akcea Therapeutics Drug Based on Gene Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Akcea Therapeutics Drug Based on Gene Therapy Product Portfolio Table 108. Akcea Therapeutics Recent Development Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Drug Based on Gene Therapy Product Image Figure 2. Global Drug Based on Gene Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Based on Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Drug Based on Gene Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Viral Gene Therapy Image Figure 8. Non-viral Gene Therapy Image Figure 9. Global Drug Based on Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Drug Based on Gene Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Drug Based on Gene Therapy Sales Value Share by Type (2021-2032) Figure 12. Neurological Diseases Image Figure 13. Cancer Image Figure 14. Other Image Figure 15. Global Drug Based on Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Drug Based on Gene Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Drug Based on Gene Therapy Sales Value Share by Application (2021-2032) Figure 18. Global Drug Based on Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Drug Based on Gene Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Drug Based on Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 21. North America Drug Based on Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Drug Based on Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Drug Based on Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Drug Based on Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Drug Based on Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Drug Based on Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 27. South America Drug Based on Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Drug Based on Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Drug Based on Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Viral Gene Therapy
  • Non-viral Gene Therapy
Applications
  • Neurological Diseases
  • Cancer
  • Other
Companies covered
  • Novartis
  • Biogen
  • Amgen
  • Sunway Biotech
  • Spark Therapeutics
  • SIBIONO
  • Sarepta Therapeutics
  • Orchard Therapeutics
  • Human Stem Cells Institute
  • Gilead Sciences
  • bluebird bio
  • AnGes
  • Alnylam Pharmaceuticals
  • Akcea Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drug Based on Gene Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drug Based on Gene Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drug Based on Gene Therapy Market Dynamics
  1. 2.1 Drug Based on Gene Therapy Industry Trends
  2. 2.2 Drug Based on Gene Therapy Industry Drivers
  3. 2.3 Drug Based on Gene Therapy Industry Opportunities and Challenges
  4. 2.4 Drug Based on Gene Therapy Industry Restraints
3 Drug Based on Gene Therapy Market by Company
  1. 3.1 Global Drug Based on Gene Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Drug Based on Gene Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Drug Based on Gene Therapy Company Ranking (2024-2026)
  4. 3.4 Global Drug Based on Gene Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Drug Based on Gene Therapy Company Product Type and Application
  6. 3.6 Global Drug Based on Gene Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drug Based on Gene Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drug Based on Gene Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drug Based on Gene Therapy Market by Type
  1. 4.1 Drug Based on Gene Therapy Type Introduction
  2. 4.1.1 Viral Gene Therapy
  3. 4.1.2 Non-viral Gene Therapy
  4. 4.2 Global Drug Based on Gene Therapy Sales Value by Type
  5. 4.2.1 Global Drug Based on Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Drug Based on Gene Therapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global Drug Based on Gene Therapy Sales Value Share by Type (2021-2032)
5 Drug Based on Gene Therapy Market by Application
  1. 5.1 Drug Based on Gene Therapy Application Introduction
  2. 5.1.1 Neurological Diseases
  3. 5.1.2 Cancer
  4. 5.1.3 Other
  5. 5.2 Global Drug Based on Gene Therapy Sales Value by Application
  6. 5.2.1 Global Drug Based on Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drug Based on Gene Therapy Sales Value by Application (2021-2032)
  8. 5.2.3 Global Drug Based on Gene Therapy Sales Value Share by Application (2021-2032)
6 Drug Based on Gene Therapy Regional Value Analysis
  1. 6.1 Global Drug Based on Gene Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drug Based on Gene Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drug Based on Gene Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drug Based on Gene Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drug Based on Gene Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Drug Based on Gene Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drug Based on Gene Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Drug Based on Gene Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drug Based on Gene Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drug Based on Gene Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drug Based on Gene Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Drug Based on Gene Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drug Based on Gene Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drug Based on Gene Therapy Sales Value Share by Country, 2025 VS 2032
7 Drug Based on Gene Therapy Country-level Value Analysis
  1. 7.1 Global Drug Based on Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drug Based on Gene Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drug Based on Gene Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drug Based on Gene Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drug Based on Gene Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drug Based on Gene Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drug Based on Gene Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Drug Based on Gene Therapy Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Biogen
  8. 8.2.1 Biogen Company Information
  9. 8.2.2 Biogen Business Overview
  10. 8.2.3 Biogen Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Biogen Drug Based on Gene Therapy Product Portfolio
  12. 8.2.5 Biogen Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Drug Based on Gene Therapy Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 Sunway Biotech
  20. 8.4.1 Sunway Biotech Company Information
  21. 8.4.2 Sunway Biotech Business Overview
  22. 8.4.3 Sunway Biotech Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sunway Biotech Drug Based on Gene Therapy Product Portfolio
  24. 8.4.5 Sunway Biotech Recent Developments
  25. 8.5 Spark Therapeutics
  26. 8.5.1 Spark Therapeutics Company Information
  27. 8.5.2 Spark Therapeutics Business Overview
  28. 8.5.3 Spark Therapeutics Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Spark Therapeutics Drug Based on Gene Therapy Product Portfolio
  30. 8.5.5 Spark Therapeutics Recent Developments
  31. 8.6 SIBIONO
  32. 8.6.1 SIBIONO Company Information
  33. 8.6.2 SIBIONO Business Overview
  34. 8.6.3 SIBIONO Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 SIBIONO Drug Based on Gene Therapy Product Portfolio
  36. 8.6.5 SIBIONO Recent Developments
  37. 8.7 Sarepta Therapeutics
  38. 8.7.1 Sarepta Therapeutics Company Information
  39. 8.7.2 Sarepta Therapeutics Business Overview
  40. 8.7.3 Sarepta Therapeutics Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sarepta Therapeutics Drug Based on Gene Therapy Product Portfolio
  42. 8.7.5 Sarepta Therapeutics Recent Developments
  43. 8.8 Orchard Therapeutics
  44. 8.8.1 Orchard Therapeutics Company Information
  45. 8.8.2 Orchard Therapeutics Business Overview
  46. 8.8.3 Orchard Therapeutics Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Orchard Therapeutics Drug Based on Gene Therapy Product Portfolio
  48. 8.8.5 Orchard Therapeutics Recent Developments
  49. 8.9 Human Stem Cells Institute
  50. 8.9.1 Human Stem Cells Institute Company Information
  51. 8.9.2 Human Stem Cells Institute Business Overview
  52. 8.9.3 Human Stem Cells Institute Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Human Stem Cells Institute Drug Based on Gene Therapy Product Portfolio
  54. 8.9.5 Human Stem Cells Institute Recent Developments
  55. 8.10 Gilead Sciences
  56. 8.10.1 Gilead Sciences Company Information
  57. 8.10.2 Gilead Sciences Business Overview
  58. 8.10.3 Gilead Sciences Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Gilead Sciences Drug Based on Gene Therapy Product Portfolio
  60. 8.10.5 Gilead Sciences Recent Developments
  61. 8.11 bluebird bio
  62. 8.11.1 bluebird bio Company Information
  63. 8.11.2 bluebird bio Business Overview
  64. 8.11.3 bluebird bio Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 bluebird bio Drug Based on Gene Therapy Product Portfolio
  66. 8.11.5 bluebird bio Recent Developments
  67. 8.12 AnGes
  68. 8.12.1 AnGes Company Information
  69. 8.12.2 AnGes Business Overview
  70. 8.12.3 AnGes Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AnGes Drug Based on Gene Therapy Product Portfolio
  72. 8.12.5 AnGes Recent Developments
  73. 8.13 Alnylam Pharmaceuticals
  74. 8.13.1 Alnylam Pharmaceuticals Company Information
  75. 8.13.2 Alnylam Pharmaceuticals Business Overview
  76. 8.13.3 Alnylam Pharmaceuticals Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Alnylam Pharmaceuticals Drug Based on Gene Therapy Product Portfolio
  78. 8.13.5 Alnylam Pharmaceuticals Recent Developments
  79. 8.14 Akcea Therapeutics
  80. 8.14.1 Akcea Therapeutics Company Information
  81. 8.14.2 Akcea Therapeutics Business Overview
  82. 8.14.3 Akcea Therapeutics Drug Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Akcea Therapeutics Drug Based on Gene Therapy Product Portfolio
  84. 8.14.5 Akcea Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst